MARKET

INO

INO

Inovio Pharmaceu
NASDAQ
1.760
+0.050
+2.92%
After Hours: 1.840 +0.08 +4.55% 19:59 11/20 EST
OPEN
1.725
PREV CLOSE
1.710
HIGH
1.775
LOW
1.620
VOLUME
7.92M
TURNOVER
--
52 WEEK HIGH
2.720
52 WEEK LOW
0.5632
MARKET CAP
329.66M
P/E (TTM)
-2.2091
1D
5D
1M
3M
1Y
5Y
1D
Inovio Pharmaceuticals (INO) Stock Offers No Clear Value Read After 110% Jump
Simply Wall St · 1d ago
Inovio Pharmaceuticals Prepares First Product Launch After VOCERYQ FDA Approval
NASDAQ · 3d ago
INOVIO: EMA Filing for VOCERYQ Supports European Expansion; Analyst Maintains $5 Price Target
TipRanks · 4d ago
INOVIO Seeks European Approval For VOCERYQ In Rare HPV-Related Disease
NASDAQ · 4d ago
Inovio submits CMA application to EMA for voceryq
TipRanks · 4d ago
INOVIO Submits Conditional Marketing Authorization Application To EMA For VOCERYQ In Adults with Recurrent Respiratory Papillomatosis
Benzinga · 4d ago
INOVIO Submits Conditional Marketing Authorization Application to European Medicines Agency for VOCERYQ™ in Adults with Recurrent Respiratory Papillomatosis
PR Newswire · 4d ago
Inovio Pharmaceuticals, Inc. Appoints Jeffrey Libson to Board of Directors
NASDAQ · 4d ago
More
About INO
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.

Webull offers Inovio Pharmaceuticals Inc stock information, including NASDAQ: INO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INO stock methods without spending real money on the virtual paper trading platform.